1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
4
Active Trials
200 recruiting
10
Rare Diseases
across 17 areas
0
News (30d)
Quiet
Texas Tech University Health Sciences Center is a company with 1 orphan drug designation across 10 rare diseases. Active clinical trials in 4 indications. 7 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Alzheimer disease | - | Des.TrialAppr. |
| acquired hyperprolactinemia | domperidone | Des.TrialAppr. |
| amyloidosis | - | Des.TrialAppr. |
| diabetes mellitus | - | Des.TrialAppr. |
| familial hyperprolactinemia | domperidone | Des.TrialAppr. |
| galactorrhoea-hyperprolactinaemia | domperidone | Des.TrialAppr. |
| hyperprolactinemia | domperidone | Des.TrialAppr. |
| in situ carcinoma | domperidone | Des.TrialAppr. |
| mitochondrial disease | - | Des.TrialAppr. |
| stomach carcinoma in situ | domperidone | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
37
overlap in 2+ diseases
0/10
candidate diseases
0
avg importance: 0
7
affecting portfolio
0% of portfolio targets high unmet need diseases
37
overlap in 2+ diseases
0/10
candidate diseases
0
avg importance: 0
7
affecting portfolio